1.	An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome Phase: Phase IV Type: Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017842, DACOGENMDS4013, Long-term treatment of Dacogen, NCT01400633
2.	Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2006-0358, NCT00398983
3.	Phase III Randomized Study of Decitabine Versus Supportive Care in Patients With Advanced Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUPERGEN-D-0007, ABCCC-010303, NCT00043381
4.	Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: CDR0000256224, EORTC-06011, SUPERGEN-EORTC-06011, GMDSG-EORTC-06011, EudraCT-2005-002830, NCT00043134
5.	Trial of Decitabine in Patients With Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DACO-016, NCT00260832
6.	An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR015037, DACOGENMYE3001, NCT01026376
7.	Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome Phase: Phase III Type: Natural history/Epidemiology Status: Completed Age: 20 to 70 Sponsor: Other Protocol IDs: H-1012-015-342, NCT01409070
8.	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 15 to 55 Sponsor: NCI, Other Protocol IDs: DM94-064, P30CA016672, MDA-DM-94064, NCI-G96-0999, CDR0000065033, NCT00002831
9.	Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 60 and under Sponsor: NCI, Other Protocol IDs: DM94-077, P30CA016672, MDA-DM-94077, NCI-G96-1000, CDR0000065034, NCT00002832
10.	Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 06-054, MSKCC-06054, NCT00382200
11.	Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 0704-07 IUCRO-0185, NCT00477386
12.	Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UPCI 07-008, NCT00715793
13.	LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: 08-0172 / 201012979, NCT00691938
14.	Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2007-0450, NCT00791271
15.	Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CASE2908, NCI-2010-00135, NCT01165996
16.	Study of Sapacitabine in Acute Myeloid Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 70 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CYC682-11, NCT01211457
17.	Phase II Study of Decitabine in Hormone-Refractory Stage D2 Prostate Cancer (Summary Last Modified 11/94) Phase: Phase II Type: Treatment Status: Completed Age: over 18 Sponsor: Protocol IDs: NCI-94-C-0002A, NCI-CPB-332
18.	Phase II Study of Decitabine for Myelodysplastic Syndromes (Summary Last Modified 12/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 15 and over Sponsor: NCI Protocol IDs: MSKCC-98017, NCI-G98-1444, NCT00003361
19.	Phase II Chemotherapy with 5-Aza-dCyd in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Uterine Cervix (Summary Last Modified 05/89) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-55857
20.	Phase II Trial of 5-Aza-2'-deoxycytidine in Patients with Advanced Squamous Cell Carcinoma, Adenocarcinoma, and Large Cell Carcinoma of the Lung Phase: Phase II Type: Treatment Status: Closed Age: 75 and under Sponsor: Protocol IDs: EORTC-16851C
21.	Phase II Chemotherapy with 5-AZA-2'-Deoxycytidine in Patients with Relapsed or Refractory Stage III/IV Hodgkin's Disease Phase: Phase II Type: Treatment Status: Closed Age: over 15 Sponsor: Protocol IDs: EORTC-20861
22.	Phase II Study of Chemotherapy with 5-Aza-2'-Deoxycytidine in Patients with Advanced Epithelial Cancer of the Ovary Phase: Phase II Type: Treatment Status: Closed Age: 70 and under Sponsor: Protocol IDs: EORTC-16851G
23.	Phase II Chemotherapy with 5-Aza-2'-deoxycytidine in Patients with Nonseminomatous Testicular or Extragonadal Germ Cell Tumors That Are Progressive, Measurable, and Metastatic (Summary Last Modified 05/88) Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: EORTC-30871
24.	Phase II Randomized Trial of 5-Aza-2'-deoxycytidine in Combination with m-AMSA or IDA in Patients with Relapsed Acute Leukemia (Summary Last Modified 05/91) Phase: Phase II Type: Treatment Status: Closed Age: 14 to 70 Sponsor: Protocol IDs: EORTC-06893
25.	Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: NCI-2012-02516, MDA-ID-02205, N01CM62202, CDR0000270678, NCI-5737, 5737, NCT00054431